Ibuprofen and Alzheimer's disease.

Basit Öğe Kaydı
dc.authorscopusid6602917963
dc.contributor.authorDokmeci D.
dc.date.accessioned2024-06-12T10:28:00Z
dc.date.available2024-06-12T10:28:00Z
dc.date.issued2004
dc.description.abstractThere is epidemiological observation that long-term treatment of patients suffering from rheumatoid arthritis with ibuprofen results in reduced risk and delayed onset of Alzheimer's disease (AD). Chronic central nervous system inflammation in AD brain is implicated in the pathology, but how ibuprofen impacts the pathogenic AD pathways is unclear. Ibuprofen, a commonly used over-the-counter nonsteroidal anti-inflammatory drug (NSAID) that is a cyclooxygenase (COX)-1 and COX-2 inhibitor as well as a peroxisome proliferator-activated receptor (PPAR) agonist, decreases the production of nitric oxide (NO), protects neurons against glutamate toxicity and decreases the production of proinflammatory cytokines. Ibuprofen crosses the blood brain barrier and suppresses neuritic plaque pathology and inflammation in AD brain. Furthermore, ibuprofen is a potent free radical scavenger, and it could reduce lipid peroxidation and free radical generation. Because of neuroprotective activity, relative safety, and its long history of use, ibuprofen is currently being developed for clinical use in AD. Ibuprofen may be a promising new therapeutic avenue for the treatment of neurodegenerative diseases such as AD.en_US
dc.identifier.endpage10en_US
dc.identifier.issn0204-8043
dc.identifier.issue2en_US
dc.identifier.pmid15506544en_US
dc.identifier.scopus2-s2.0-16544364566en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage5en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17041
dc.identifier.volume46en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofFolia medicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIbuprofen; Nonsteroid Antiinflammatory Agent; Alzheimer Disease; Drug Effect; Human; Immunology; Immunomodulation; Inflammation; Pathology; Review; Rheumatoid Arthritis; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Ibuprofen; Inflammation; Neuroimmunomodulationen_US
dc.titleIbuprofen and Alzheimer's disease.en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu